News

C​andida auris

An Unusual Yeast Causing Serious Infection

Over the past number of years discussion surrounding Candida auris has continued to increase. This pathogen is regularly discussed by the media and governmental bodies. It is of high concern to healthcare facilities. But what is Candida auris and why is it gaining so much attention?

 

Candida auris is a fungal pathogen, to be more specific, it is a type of yeast. This pathogen was first reported in Japan in 2009 and has since been linked with healthcare associated infections (HAIs) on five continents (1). C. auris control is challenging due to the difficulty in identifying this pathogen in the clinical laboratory. Moreover, C. auris often exhibits high levels of multi drug resistance, leading to high rates of treatment failure with invasive infections (2). The United States Centers for Disease Control and Prevention (CDC) map new case reports worldwide (https://www.cdc.gov/fungal/candida-auris/tracking-c-auris.html).

 

As of January 31st, 2019, a total of 560 confirmed clinical cases have been identified in the U.S.

The most commonly observed invasive infection associated with C. auris has been blood stream infections, with mortality in the range of 30 to 60%. Patients involved generally have high healthcare exposure, however, infection may not be apparent until weeks after initial admission (2). The best treatment practice for C. auris infection has not been defined.

C. auris appears to spread via patients and the environment. It has be isolated from the skin of affected patients as well a patient contact areas, such as sinks, medical equipment, furniture and mattresses (3, 4). Recent investigations suggest quaternary ammonium compounds may not be effective against C. auris (5). The US CDC recommend that sporicidal disinfectants (those listed on the U.S. EPA List K) be used where C. auris is of concern and provide several other points of interest in relation to C. auris transmission control, such as hand hygiene and contact precautions (https://www.cdc.gov/fungal/candida-auris/c-auris-infection-control.html).

 

There is still a lot to learn regarding this pathogen, such as its origin in the natural environment, the reason for its sudden emergence and high antifungal resistance. Healthcare workers should remain ever vigilant for C. auris where Candida spp. infection is suspected due to its impact on patient mortality. Undoubtedly control of these outbreaks will prove a challenge until more information about this unusual pathogen become available. Providing care in accordance with best practice outlined by the CDC will be key until more defined control mechanisms become apparent.

 

 

1. Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. 2009. Candida auris sp . nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol. Immunol: 53:41–44

2. Spivak ES, Hanson E. 2018. Candida auris : an Emerging Fungal Pathogen. J. Clin. Microbiol. 56:1–10.

3. Vallabhaneni S, Kallen A, Tsay S, Chow N, Welsh R, Kerins J, Kemble SK, Pacilli M, Black SR, Landon E, Ridgway J,Palmore TN, Zelzany A, Adams EH,Quinn M, Chaturvedi, S, Greenko J, Fernandez R, Southwick K, Furuya EY, Calfee DP, Hamula C, Patel G, Barrett P, Lafaro P, Berkow EL, Moulton-Meissner H, Noble-Wang J,Fagan RP, Jackson BR, Lockhart SR, Litvintseva AP, Chiller TM. 2017. Investigation of the First Seven Reported Cases of Candida auris , a Globally Emerging Invasive Multidrug-Resistant Fungus — United States , May 2013 – August 2016. Amer. J. Transplant. 17:296-299

4.Schelenz S, Hagen F, Rhodes JL, Abdolrasouli A, Chowdhary A, Hall A, Ryan L, Shackleton J, Trimlett R, Meis JF, Armstrong-james D, Fisher MC. 2016. First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrob Resist Infect Control. 5:35.

5. Cadnum JL, Shaikh AA, Christina T, Sankar T, Jencson AL, Larkin EL, Ghannoum MA, Donskey CJ. 2017. Effectiveness of Disinfectants Against Candida auris and Other Candida Species. Infect. Control and Hosp. Emidemiol. 38:1–4.

 

 

New Jersey:  Dry surface biofilm has been found to exist on 93% of all critical care area hospital surfaces. Over 50% of these biofilms contain Mutant Germs which are resistant to antibiotics resulting in hospital acquired infections (HAIs)

The EPA has this week registered the first product to be effective against these biofilms.

Medentech are announcing the efficacy of their effervescent NaDCC disinfection tablet for cleaning and disinfection.

Michael Gately CEO Medentech: “This is something I might never see in my lifetime again. Biofilms give germs 1,000 times more protection, thus standard disinfectants such as bleach, hydrogen peroxide, or ultraviolet light, don’t work properly. The EPA has developed a new efficacy protocol and I am delighted to say that our NaDCC effervescent disinfection tablets are the first and only product to have passed this test”.

 

About Dry Surface Biofilm

Most germs on hospital surfaces live in a biofilm. A biofilm comprises any group of microorganisms in which cells stick to a surface. These adherent cells become embedded within a slimy extracellular matrix. Following initial research by Professor Karen Vickery, Hu et al have evidenced the existence of biofilm on 93% of all critical care area surfaces with over 50% of these containing mutant germs.

 About HAIs & Multi Drug Resistant Bacteria

Mutant germs are multi drug resistant organisms which cause HAIs. Approximately 722,000 HAIs occur annually in U.S. acute care hospitals resulting in 75,000 deaths (CDC 2014).

 About the Solution:

A new tool has emerged as a broad-spectrum cleaner & disinfectant that eliminates pathogens without damaging surfaces.  

Klorkleen 2 disinfectant is the first product to receive EPA registration for its Biofilm efficacy (EPA  71847-7).  Klorkleen 2 is a powerful surface disinfectant based on sodium dichloroisocyanurate (NaDCC) with registered claims as a hospital grade disinfectant that meets the surface disinfection requirements of OSHA Bloodborne Pathogens Standards. Kill claims include Clostridium difficile spores, Norovirus, Tb, CRE.

 

 By Mark Hodgson

Aug 14 2018